Data-Gouv-ML/pcri-informations-sur-les-projets-laureats huggingface dataset:
Bridging the gap between Gas Emissions and geophysical observations at active volcanoes (BRIDGE)

Framework: FP7 — Ideas
Programme: European Research Council
Theme: European research council
Destination: Starting grants
Action type: Support for frontier research (ERC)
Panel: Earth system science
Countries involved: Italy,Italy
Call:  (ERC-2012-StG_20111012, 2012)
Start date: 2012-10-01
End date: 2016-09-30
Duration (months): 48.0
Total project cost (EUR): 1496222.0
EU funding (EUR): 1496222.0
Participants: 2
Project status: CLOSED

In spite of their significance in a variety of volcanological aspects, gas observations at volcanoes have lagged behind geophysical studies for a long time. This has primarily reflected the inherent technical limitations met by gas geochemists in capturing volcanic gas properties (chemistry and flux) at high-rate (1 Hz), and using permanent instrumental arrays. The poor temporal resolution of volcanic gas observations has, in addition, precluded the real-time analysis of fast-occurring volcanic processes, as those occurring shortly prior to eruptions, therefore generally limiting the use of gas geochemistry in volcanic hazard assessment. However, the recent progresses made by modern multi-component/high frequency measurement techniques now open the way for decisive step ahead in the current state-of-the-art to be finally attempted. The BRIDGE research proposal has the ambitious goals to bridge the existing technological gap between geochemical and geophysical observations at volcanoes. This will be achieved by designing, setting up, and deploying in the field, innovative instruments for 1 Hz observations of volcanic SO2 and CO2 fluxes. From this, the co-acquired volcanic gas and geophysical information will be then combined within a single interpretative framework, therefore contributing to fill our current gap of knowledge on fast (timescales of seconds/minutes) degassing processes, and to deeper exploration of the role played by gas exsolution from (and migration through) silicate liquids as effective source mechanism of the physical signals (e.g., LP and VLP seismicity, and tremor) measured at volcanoes. Finally, this combined volcanic gas-geophysical approach will be used to yield improved modelling/understanding of a variety of volcanic features, including modes/rates of gas separation from magmas, mechanisms of gas flow in conduits, and trigger mechanisms of explosive volcanic eruptions.

Keywords: volcanic degassing,gas and geophysical volcano monitoring
Polypharmacy in chronic diseases: Reduction of Inappropriate Medication and Adverse drug events in elderly populations by electronic Decision Support (PRIMA-EDS)

Framework: FP7 — Cooperation
Programme: Health
Destination: Translating research for human health
Action type: Collaborative project
Countries involved: Germany,Germany,United Kingdom,Austria,Finland,Italy
Call:  (FP7-HEALTH-2012-INNOVATION-1, 2012)
Start date: 2012-12-01
End date: 2017-11-30
Duration (months): 60.0
Total project cost (EUR): 5978745.86
EU funding (EUR): 4618515.0
Participants: 6
Project status: CLOSED

Background: Treatment of chronic diseases in the elderly with polypharmacy poses a threat to patient outcome and involves extensive costs. Little evidence exists regarding the benefits of polypharmacy, but rising evidence shows its harmful effects. Several approaches to reduce polypharmacy have been proposed, but none have been evaluated using clinically relevant endpoints. Aims: Based on a systematic review we will gather current best evidence and develop recommendations to optimize treatment of polymorbid elderly with cardiovascular disease, heart failure, hypertension, atrial fibrillation, diabetes mellitus type 2, musculoskeletal disorders, COPD, and mental diseases. We will then design an electronic decision support (eDS) tool incorporating the recommendations to be applied in primary care. The tool will be evaluated in a randomised controlled trial (RCT) to show that reduction of polypharmacy in the treatment of the target-diseases is beneficial and safe. Using the results of the RCT, the eDS-tool will be optimized and then disseminated for general utilization. Workplan: The project is scheduled for 4 years and will contain 12 work packages. WP1 comprises management of the project. The evidence regarding treatment of chronic diseases gathered within WP2 will be used to develop the eDS tool and an electronic case report form (eCRF) in WPs 3-4. After recruitment of surgeries and patients, and implementation of the tool in WP 5, the tool will be evaluated within a cluster-randomized controlled trial (WPs 6-10). The results of the RCT will be used to optimize the eDS tool (WP 11) which will then be disseminated (WP 12). Impact: The project will contribute to the EIP “Active and Healthy Ageing”. It will improve treatments suited to the needs of older people and lower health care costs by promoting standardized care and reducing hospital admissions. The tool will be exploited by one of the partners (Duodecim Medical Publications) to achieve widespread implementation

Keywords: chronic diseases,elderly,polypharmacy,patient safety,ade,electronic decision support,outcome,hospital admission rate,mortality
Phase I/II Gene Therapy Trial of Fanconi anemia patients with a new Orphan Drug consisting of a lentiviral vector carrying the FANCA gene: A Coordinated International Action (EUROFANCOLEN)

Framework: FP7 — Cooperation
Programme: Health
Destination: Translating research for human health
Action type: Collaborative project
Countries involved: Spain,France,United Kingdom,Spain,France,Germany,Germany
Call:  (FP7-HEALTH-2012-INNOVATION-1, 2012)
Start date: 2013-01-01
End date: 2018-12-31
Duration (months): 72.0
Total project cost (EUR): 7200944.9
EU funding (EUR): 5380169.75
Participants: 12
Project status: CLOSED

Fanconi anemia (FA) is a rare inherited syndrome characterized by the early development of bone marrow failure and increasing predisposition to cancer with age. Allogeneic hematopoietic cell transplantation (alloHCT) is the only curative therapy for hematopoietic manifestations of FA, although associated with complications arising from myeloablation, graft versus host disease and increased incidence of squamous cell carcinoma. The genetic correction of autologous hematopoietic stem cells (HSC) with lentiviral vectors constitutes a recent and safe alternative for the treatment of different genetic diseases affecting mature cells from different tissues and/or committed progenitors of the hematopoietic system. One of the key features of FA that make it a unique disease for gene therapy approaches rely on the characteristic proliferation defect that is already evident in the very primitive HSCs. Thus, a marked survival advantage would be expected from corrected HSCs, potentially allowing normalization of hematopoiesis in the absence or after mild conditioning. Difficulties in the collection of sufficient numbers of HSC from FA patients and the use of sub-optimal transduction protocols with gammaretroviral vectors limited the success of FA gene therapy trials conducted 10 years ago in the USA. Our innovative approach to develop for the first time an efficient and safe gene therapy of FA is based on two recent innovations: 1) Discovery of potent HSC mobilizers, such as plerixafor, and 2) Development of a new lentiviral vector by members of this Consortium, designed as Orphan Drug by the EC in December 2010. The principal objective of this Project is, therefore, the development of a multicentric Phase I/II gene therapy trial for FA-A patients, based on the genetic correction of plerixafor+G-CSF mobilized HSCs with the novel lentiviral vector, accompanied by comprehensive and groundbreaking safety and efficacy patient monitoring studies.

Keywords: fanconi anemia,gene therapy,lentiviral vectors,stem cells,orphan drugs
Development of COMBInatorial BIOmarkers for subclinical atherosclerosis (COMBI-BIO)

Framework: FP7 — Cooperation
Programme: Health
Destination: Translating research for human health
Action type: Collaborative project
Countries involved: United Kingdom,Greece,Netherlands,Germany,United States
Call:  (FP7-HEALTH-2012-INNOVATION-1, 2012)
Start date: 2012-10-01
End date: 2014-09-30
Duration (months): 24.0
Total project cost (EUR): 3878715.19
EU funding (EUR): 2964695.86
Participants: 6
Project status: CLOSED

Systems biology involves the analysis of relationships among the elements in a system, viewed as an integrated and interacting network of genes, proteins and biochemical reactions. We have pioneered the use of metabolic profiling and the metabolome-wide association study (MWAS) approach, involving high-throughput spectroscopic screening, to capture comprehensive data on a range of exposures affecting disease risk from genetic, lifestyle, gut microbial and xenobiotic sources. Cardiovascular disease is the leading cause of death worldwide. It is a late manifestation of the pathophysiological processes leading to development of atherosclerosis, starting early in life. There is urgent clinical need to identify predictive combinatorial biomarkers for subclinical atherosclerosis, to allow preventive/treatment strategies to be instituted early in the disease process. Our proposal brings together leaders in metabolic profiling and computational medicine for analysis of multi-omics data, and leading European/US prospective cohorts with subclinical atherosclerosis measurements. We propose to apply untargeted metabolic profiling using both proton Nuclear Magnetic Resonance spectroscopy (1H NMR) and Mass Spectrometry (MS) to discover novel biomarkers for subclinical atherosclerosis in stored serum samples from 4,000 people, with validation in stored samples from a further 4,000 people. We will develop and apply methods for investigating cross-platform (NMR, MS) and multi-omics (genome-wide, metabolome-wide) relationships to gain better understanding of underlying biochemical connectivities and pathways. For identified/validated novel and established/emerging biomarkers, we will develop a predictive combinatorial set of biomarkers and risk scores for subclinical atherosclerosis. This research should lead to identification of a novel set of combinatorial biomarkers, with potential to develop low-cost tests for subclinical atherosclerosis, for translation into clinical practice.

Keywords: systems biology,systems medicine,computational medicine,metabonomics,metabolic profiling,biomarker,subclinical atherosclerosis,gwas,risk score
EPIGENETICS FOR FEMALE PERSONALIZED CANCER CARE (EPI-FEM-CARE)

Framework: FP7 — Cooperation
Programme: Health
Destination: Biotechnology, generic tools and medical technologies for human health
Action type: Collaborative project
Countries involved: United Kingdom,Germany,Switzerland,United Kingdom,Germany,Czechia
Call:  (FP7-HEALTH-2012-INNOVATION-1, 2012)
Start date: 2012-11-01
End date: 2016-04-30
Duration (months): 42.0
Total project cost (EUR): 7633928.71
EU funding (EUR): 5875387.0
Participants: 6
Project status: CLOSED

CLINICAL NEED Every year in the EU ~45,300 and 330,000 women are diagnosed with ovarian and breast cancer respectively & 28,800 and 90,000 of these two groups of women will die as a consequence of these diseases. Currently there are no tools available that allow for: a) Effective screening of ovarian and/or breast cancer of sufficient sensitivity and specificity to avoid potential over-diagnosis, or; b) Stratification of patients into optimal personalised therapy regimes in ovarian/breast cancer. EpiFemCare ADVANCES Progress in personalised cancer medicine will only be possible with the development of bioassays involving the analysis of easy accessible biomaterials that contain stable target molecules reflective of disease. We will establish and clinically validate a series of blood tests based upon DNA methylation technology that will facilitate both early detection and prediction of therapeutic outcome in breast and ovarian cancer. CONSORTIUM Our pan-European academic-industrial consortium demonstrates diverse clinical, scientific & industrial expertise. We have access to the latest state of the art technologies and, integrally, the best available cohort and clinical trial sample sets required to ensure the success of the EpiFemCare program. GATC-Biotech and Genedata are Europe’s leading providers of DNA sequencing and bioinformatics for biomarker development and have developed serum DNA based prenatal tests. The clinical partners have access to unique cohort and clinical samples collected from >200,000 women well in advance of disease (UK Collaborative Trial of Ovarian Cancer Screening) or before and during treatment (SUCCESS Trial). IMPACT As a result of refined and improved patient stratification, EpiFemCare will: - Reduce the late stage presentation of ovarian & breast cancer by 50% - Reduce the requirement for 50% of breast cancer patients to have adjuvant therapies - Reduce female cancer related fatalities as well as treatment-related morbidity by 20%

Keywords: epigenetics,female cancers,diagnosis,monitoring,ovarian cancer and breast cancer
Diagnostic and prognostic biomarkers for inflammatory bowel disease IBD-BIOM (IBD-BIOM)

Framework: FP7 — Cooperation
Programme: Health
Destination: Translating research for human health
Action type: Collaborative project
Countries involved: United Kingdom,Croatia,United Kingdom,France,Italy,Netherlands,Germany,United States,Australia,Netherlands
Call:  (FP7-HEALTH-2012-INNOVATION-1, 2012)
Start date: 2012-10-01
End date: 2016-09-30
Duration (months): 48.0
Total project cost (EUR): 8550991.99
EU funding (EUR): 5999611.0
Participants: 11
Project status: CLOSED

Inflammatory bowel diseases affect 0.8% of the Europeans, and are associated with high morbidity, definite mortality and an increasing economic burden. Current diagnostic tools and therapeutics for IBD are unsatisfactory. Development of biomarkers allowing insights into pathogenesis, prognosis and targeted therapy is a major unmet need. This programme addresses that need. IBD-BIOM is a multidisciplinary consortium of leading academic and industrial SME researchers in inflammatory bowel disease, genomics, glycomics, glycoproteomics and activomics. Recent genome-wide association studies performed by IBD-BIOM partners have identified nearly 100 genes associated with IBD, but clinical application of these is so far limited. IBD-BIOM will capitalise on its existing high quality clinical, genetic, biochemical and immunological data and biological samples on over 6000 very well characterised IBD patients and controls by exploiting novel technological approaches made available through the expertise and global leading position of IBD-BIOM partners. These comprise cutting edge epigenetic, glycomic, glycoproteomic and activomic approaches which were all previously reported to be associated with inflammation and disturbances to the immune system. The inclusion of these complementary analyses in the diagnostics of IBD should also facilitate elucidation of pathways through which environmental exposures influence IBD risk and progression. A complex systems biology approach will be used to integrate, interrogate and understand this multidimensional dataset to identify novel early diagnostic and prognostic biomarkers and new targets for therapeutic intervention. The track record of achievement of IBD-BIOM partners coupled to the central and leading positions of the research-intensive SME partners in IBD-BIOM is a strong indication that the ambitions work programme will be achieved and a framework to facilitate swift conversion of research discoveries into commercial products.

Keywords: inflammatory bowel disease,genetics,genomics,glycomics,glycoproteomics,activomics,immunology
To decipher the optimal management of systemic sclerosis (DESSCIPHER)

Framework: FP7 — Cooperation
Programme: Health
Destination: Translating research for human health
Action type: Collaborative project
Countries involved: Germany,Switzerland,France,Italy,Italy,United Kingdom,Germany,Hungary,United Kingdom,France,Belgium,Germany
Call:  (FP7-HEALTH-2012-INNOVATION-1, 2012)
Start date: 2012-12-01
End date: 2015-11-30
Duration (months): 36.0
Total project cost (EUR): 3791344.57
EU funding (EUR): 2999835.0
Participants: 15
Project status: CLOSED

The current approach to diagnosis and management of the rare disease systemic sclerosis (SSc) is based on American College of Rheumatology criteria with low sensitivity and few validated recommendations for the therapy of the disease and its manifold organ manifestations. To overcome these shortcomings, the DeSScipher project will use the multinational, prospective and open EUSTAR (Scleroderma Trials and Research group of the European League Against Rheumatism) SSc cohort based on the established MEDSonline database which covers >30 data items and will evolve into a multimodular tool to answer step-by-step all immanent questions in a long-term setting according to the nature of the disease. The resulting progress will address functionally disabling manifestations affecting the hands (digital ulcers and arthritis), and compare the efficacy and safety of off-label drugs in the treatment of vital organ manifestations. Specifically, the DeSScipher project will evaluate (i) the utility of a combination of easy-to-perform clinical and laboratory investigations in combination with capillaroscopy for identifying SSc patients at risk for the development of digital ulcers at an early stage (ii) the prevention and treatment of digital ulcers and hand arthritis in order to improve long-term disability and quality of life, (iii) the efficacy of different immunosuppressive agents in attenuating or inhibiting pulmonary fibrosis, (iv) the optimal treatment options for reducing morbidity and mortality of pulmonary hypertension and severe heart disease in SSc. Based on the results of these observational trials, the DeSScipher project will develop evidence-based clinical guidelines for the future management of adult and juvenile SSc to be disseminated widely and rapidly to physicians and patients. Novel outcome measures will also be provided as a basis for future clinical trials.

Keywords: systemic sclerosis,observational trials,organ dysfunction,therapeutic intervention,clinical management,outcome measures,prognosis,off-label drugs,rare disease,efficacy,safety
Pathogen COinfection: HIV, Tuberculosis, Malaria and Hepatitis C virus (PATHCO)

Framework: FP7 — Cooperation
Programme: Health
Destination: Translating research for human health
Action type: Collaborative project
Countries involved: United Kingdom,United Kingdom,France,Germany,United Kingdom,China,South Africa,Italy,Netherlands
Call:  (FP7-HEALTH-2012-INNOVATION-1, 2012)
Start date: 2012-11-01
End date: 2017-10-31
Duration (months): 60.0
Total project cost (EUR): 7824811.24
EU funding (EUR): 5909690.0
Participants: 11
Project status: CLOSED

Acquired immune deficiency (AIDS), tuberculosis (TB) and malaria are the primary infectious diseases causing death world wide. In addition to these pathogens, 170 million people are infected with hepatitis C virus (HCV), which leads to chronic liver disease. Because of shared routes of transmission, HCV co-infection is recognized as a major cause of morbidity and mortality among HIV-1 infected persons. The epidemiology and clinical features of co-infected subjects are well documented, however, there is a paucity of basic scientific studies addressing the interactions between these pathogens. There is undoubtedly a complex interplay between pathogens and the host immune response. This was highlighted when the Merck HIV-1 vaccine trial was halted due to increased HIV-1 transmission amongst vaccine recipients with previous adenovirus infection, suggesting that immune responses specific for adenovirus vector antigens were detrimental. We propose that pathogen evasion and dysregulation of host immune responses plays a key role in co-infection associated morbidity. We will test this hypothesis by establishing in vitro and ex vivo co-infection model systems to study pathogen interactions and assess the effect(s) of co-infection on innate signalling and adaptive immune responses. We will develop new approaches to dissect pathogen interactions, ranging from the genesis of fluorescent labelled viruses to state-of-the-art tissue explant models and novel humanised mouse models. Translational studies of co-infected patients will ascertain pathogen-specific effects on innate and adaptive immune responses and the consequences for disease progression. It is imperative that such interactions are elucidated before proceeding with new prophylactic or therapeutic strategies aimed at curtailing pathogen transmission or disease progression in co-infected individuals. We specifically address the call of understanding the basic biology of co-pathogen interactions and immunity.

Keywords: hiv-1,hcv,malaria and tuberculosis,innate and adaptive immune responses,explant tissue culture systems and humanized mice model systems.
Repair of Diabetic Damage by Stromal Cell Administration (REDDSTAR)

Framework: FP7 — Cooperation
Programme: Health
Destination: Translating research for human health
Action type: Collaborative project
Countries involved: Ireland,United Kingdom,Portugal,Germany,Germany,Ireland,Denmark,Netherlands,United States
Call:  (FP7-HEALTH-2012-INNOVATION-1, 2012)
Start date: 2012-11-01
End date: 2016-10-31
Duration (months): 48.0
Total project cost (EUR): 8190280.8
EU funding (EUR): 5894387.0
Participants: 10
Project status: CLOSED

50 million diabetic EU citizens are using approved anti-diabetic agents to control their glycaemia. However, suboptimal glycemic control leads to 6 progressive diabetic complications, namely: nephropathy, retinopathy, cardiomyopathy, neuropathy and foot ulceration. In 2010, 11% of EU adult deaths (634,000) were caused by diabetic complications. These distinct disorders have few effective medicines and present challenging management issues for clinicians. Stromal Stem Cells (SSC) are a mixed population of plastic-adherent (PA) cells isolated from adult bone marrow. PA-SSC secrete potent immunosuppressive and angiogenic proteins and over 100 clinical trials are testing PA-SSC in 40 distinct autoimmune and ischemic diseases. Notably, preclinical studies show a single intravenous administration of un-modified PA-SSC can control rodent hyperglycaemia, prompting 10 recent clinical safety studies in diabetic patients. REDDSTAR will comprehensively examine if SSC can safely repair all 6 damaged tissues and control glycaemia in three different species. To facilitate this we identified an antibody (S2) that prospectively isolates comparable, equivalent S2+SSC from human, rat, mouse and rabbit marrow, enabling testing of pure S2+/- SSC and mixed PA-SSC from each species for the first time. Furthermore, separation of PA-SSC into S2+ and S2- fractions reveal functionally distinct populations. REDDSTAR partners have collectively developed five distinct clinically-relevant in vivo models of the 6 key diabetic complications. We will assess if S2+, S2- and PA-SSC exert differing control of glycaemia and tissue repair in each model. Finally, REDDSTAR partners are developing the first benchtop GMP-grade nanosorter, enabling clinical purification of S2+ and S2- SSC for human safety trials. We will dissect how S2+ and S2- SSC simultaneously repair tissue damage and maintain glycaemic control, an effect not observed with any current therapy.

Keywords: stem cells,diabetes,antibody,glycaemia,vascular complications,novel reagents